Back to News
Market Impact: 0.35
Agomab Reports Positive STENOVA Data For Ontunisertib
Source: Nasdaq
Healthcare & Biotech
Agomab Therapeutics reported positive 48-week open-label extension results from its Phase 2a STENOVA trial of ontunisertib in patients with fibrostenosing Crohn's disease. The positive clinical update may support further development of the drug candidate and could move AGMB shares, though no efficacy or safety metrics were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
AGMB0.80
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today
- This biotech making precision medicines for cancer could nearly triple, says JPMorgan
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Research Systems for Hedge Funds: A Pilot Design
- Weekly Update: New Reporting Features, UI Improvements, and Chat Optimizations